Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13026905 | 0.83 | CHRNA7 (0.41) | ESR2ESR1 | |
| SCHEMBL19790112 | 0.81 | PPARG (0.44) | PSMB5 | |
| SCHEMBL8301882 | 0.79 | OPRM1 (0.39) | OPRM1OPRK1CYP3A4 | |
| SCHEMBL16870511 | 0.79 | ALDH1A1 (0.42) | CYP3A4 | |
| SCHEMBL13282134 | 0.79 | OPRM1 (0.39) | OPRM1OPRK1CYP3A4 | |
| SCHEMBL15179215 | 0.79 | ALDH1A1 (0.42) | CYP3A4 | |
| SCHEMBL27798365 | 0.78 | ESR2 (0.46) | ESR2ESR1NR3C1PGRNR3C2 | |
| SCHEMBL14942927 | 0.75 | ESR1 (0.56) | ESR2ESR1OPRM1OPRK1 | |
| SCHEMBL7637685 | 0.75 | ESR1 (0.56) | ESR2ESR1OPRM1OPRK1 | |
| SCHEMBL8231892 | 0.75 | ESR1 (0.56) | ESR2ESR1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170101438-A1 | COSMETIC OR PHARMACEUTICAL METHODS FOR THE TREATMENT AND/OR CARE OF THE SKIN AND/OR HAIR USING TRIPEPTIDES CAPABLE OF STIMULATING CYCLIC ADENOSINE MONOPHOSPHATE SYNTHESIS | LIPOTEC, S.A. | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101438-A1 | COSMETIC OR PHARMACEUTICAL METHODS FOR THE TREATMENT AND/OR CARE OF THE SKIN AND/OR HAIR USING TRIPEPTIDES CAPABLE OF STIMULATING CYCLIC ADENOSINE MONOPHOSPHATE SYNTHESIS | MC1R, ADORA3, AMPD3 | ESR2 3886/4885ESR1 4564/4885NR3C1 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.